Biogen Inc. said it plans to make a $100 million upfront payment to Samsung Bioepis to acquire the rights to commercialize biosimilar versions of Lucentis and Eylea, two blockbuster eye drugs. Samsung Bioepis is a joint venture founded in 2012 between the Cambridge, Mass.-based biotech and Samsung , the Korean conglomerate. Biogen said it will record a $65 million charge to its research and development expenses as a result of the transaction, which also includes potential additional milestone payments of up to $210 million. Biogen’s stock is down 2.9% for the year, while the S&P 500 is up 23%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
This article does not constitute investment advice. We are not affiliated or responsible for content hosted on 3rd-party sites in any way.